Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models

References

• Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–12. doi:10.1126/science.1690918.
   PubMed Web of Science ®Google Scholar
• Ulmer JB. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259(5102):1745–9. doi:10.1126/science.8456302.
   PubMed Web of Science ®Google Scholar
• Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 1993;90(9):4156–60. doi:10.1073/pnas.90.9.4156.
   PubMed Web of Science ®Google Scholar
• Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol. 1998;16(9):867–70. doi:10.1038/nbt0998-867.
   PubMed Web of Science ®Google Scholar
• Felgner PL, Felgner PL, Gadek TR, Holm M, Roman R., Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA. 1987;84(21):7413–7. doi:10.1073/pnas.84.21.7413.
   PubMed Web of Science ®Google Scholar
• Johnston SA, Tang DC. Gene gun transfection of animal cells and genetic immunization. Methods Cell Biol. 1994;43 Pt A:353–65.
   PubMed Web of Science ®Google Scholar
• Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther. 2002;9(24):1647–52. doi:10.1038/sj.gt.3301923.
   PubMed Web of Science ®Google Scholar
• Sardesai NY, Wei ner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011;23(3):421–9. doi:10.1016/j.coi.2011.03.008.
   PubMed Web of Science ®Google Scholar
• Tomizawa M, Shinozaki F., Motoyoshi Y., Sugiyama T., Yamamoto S., Sueishi M. Sonoporation: gene transfer using ultrasound. World J Methodol. 2013;3(4):39–44. doi:10.5662/wjm.v3.i4.39.
   PubMedGoogle Scholar
• Kichaev G, Mendoza JM, Amante D, Smith TR, McCoy JR, Sardesai NY, Broderick KE. Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses. Hum Vaccin Immunother. 2013;9(10):2041–8. doi:10.4161/hv.25272.
   PubMed Web of Science ®Google Scholar
• Sheridan C. First COVID-19 DNA vaccine approved, others in hot pursuit. Nat Biotechnol. 2021;39(12):1479–82. doi:10.1038/d41587-021-00023-5.
   PubMedGoogle Scholar
• Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–75. doi:10.1016/j.immuni.2005.06.008.
   PubMed Web of Science ®Google Scholar
• Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–94. doi:10.1038/s41578-021-00358-0.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–38. doi:10.1056/NEJMoa2028436.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Follmann D, Neuzil KM, August A, Clouting H, Fortier G, Deng W, Han S, et al. Phase 3 trial of mRNA-1273 during the Delta-variant surge. N Engl J Med. 2021;385(26):2485–7. doi:10.1056/NEJMc2115597.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-Based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50. doi:10.1056/NEJMoa2027906.
   PubMed Web of Science ®Google Scholar
• Barnes CO, West AP, Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, Koranda N, Gristick HB, Gaebler C, Muecksch F, et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell. 2020;182(4):828–42 e16. doi:10.1016/j.cell.2020.06.025.
   PubMed Web of Science ®Google Scholar
• Tebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, Andrade VM, Morrow MP, Kraynyak K, Agnes J, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial. EClinicalMedicine. 2021;31:100689. doi:10.1016/j.eclinm.2020.100689.
   PubMedGoogle Scholar
• Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, Gary EN, Walker SN, Schultheis K, Purwar M, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601. doi:10.1038/s41467-020-16505-0.
   PubMed Web of Science ®Google Scholar
• Munoz-Fontela C, Dowling WE, Funnell SGP, Gsell P-S, Riveros-Balta AX, Albrecht RA, Andersen H, Baric RS, Carroll MW, Cavaleri M, et al. Animal models for COVID-19. Nature. 2020;586(7830):509–15. doi:10.1038/s41586-020-2787-6.
   PubMed Web of Science ®Google Scholar
• Chu H, Chan JF, Yuen KY. Animal models in SARS-CoV-2 research. Nat Methods. 2022;19(4):392–4. doi:10.1038/s41592-022-01447-w.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–71. doi:10.1038/s41586-020-2622-0.
   PubMed Web of Science ®Google Scholar
• Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Güler A, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–9. doi:10.1038/s41586-021-03275-y.
   PubMed Web of Science ®Google Scholar
• Figure schematics created with biorender.com.
   Google Scholar
• Oyaert M, De Scheerder M-A, Van Herrewege S, Laureys G, Van Assche S, Cambron M, Naesens L, Hoste L, Claes K, Haerynck F, et al. Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients. Front Immunol. 2022;13:858399. doi:10.3389/fimmu.2022.858399.
   PubMed Web of Science ®Google Scholar
• Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, Morrocchi E, Colagrossi L, Russo C, Zaffina S, et al. Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies. Front Immunol. 2021;12:727850. doi:10.3389/fimmu.2021.727850.
   PubMed Web of Science ®Google Scholar
• Shaan Lakshmanappa Y, Elizaldi SR, Roh JW, Schmidt BA, Carroll TD, Weaver KD, Smith JC, Verma A, Deere JD, Dutra J, et al. SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Nat Commun. 2021;12(1):541. doi:10.1038/s41467-020-20642-x.
   PubMed Web of Science ®Google Scholar
• Konrath KM, Liaw K, Wu Y, Zhu X, Walker SN, Xu Z, Schultheis K, Chokkalingam N, Chawla H, Du J, et al. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection. Cell Rep. 2022;38(5):110318. doi:10.1016/j.celrep.2022.110318.
   PubMed Web of Science ®Google Scholar
• Xu Z, Wise MC, Chokkalingam N, Walker S, Tello‐Ruiz E, Elliott STC, Perales‐Puchalt A, Xiao P, Zhu X, Pumroy RA, et al. In vivo assembly of nanoparticles achieved through synergy of structure-Based protein engineering and synthetic DNA generates enhanced adaptive immunity. Adv Sci (Weinh). 2020;7(8):1902802. doi:10.1002/advs.201902802.
   PubMedGoogle Scholar
• Alameh MG, Tombácz I, Bettini E, Lederer K, Ndeupen S, Sittplangkoon C, Wilmore JR, Gaudette BT, Soliman OY, Pine M, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54(12):2877–92 e7. doi:10.1016/j.immuni.2021.11.001.
   PubMed Web of Science ®Google Scholar
• Halpin S, O’Connor R, Sivan M. Long COVID and chronic COVID syndromes. J Med Virol. 2021;93(3):1242–3. doi:10.1002/jmv.26587.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat Rev Immunol. 2023;23(3):189–99. doi:10.1038/s41577-022-00784-3.
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev. 2022;310(1):6–26. doi:10.1111/imr.13091.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, Gumina RJ, Liu S-L. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med. 2022;14(637):eabn8057. doi:10.1126/scitranslmed.abn8057.
   PubMed Web of Science ®Google Scholar
• Horne EMF, Hulme WJ, Keogh RH, Palmer TM, Williamson EJ, Parker EPK, Green A, Walker V, Walker AJ, Curtis H, et al. Waning effectiveness of BNT162b2 and ChAdOx1 COVID-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. BMJ. 2022;378:e071249. doi:10.1136/bmj-2022-071249.
   PubMedGoogle Scholar
• Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–63. doi:10.1038/s41586-021-04385-3.
   PubMed Web of Science ®Google Scholar
• Kotaki R, Adachi Y, Moriyama S, Onodera T, Fukushi S, Nagakura T, Tonouchi K, Terahara K, Sun L, Takano T, et al. SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine. Sci Immunol. 2022;7(70):eabn8590. doi:10.1126/sciimmunol.abn8590.
   PubMed Web of Science ®Google Scholar
• Sievers BL, Chakraborty S, Xue Y, Gelbart T, Gonzalez JC, Cassidy AG, Golan Y, Prahl M, Gaw SL, Arunachalam PS, et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci Transl Med. 2022;14(634):eabn7842. doi:10.1126/scitranslmed.abn7842.
   PubMed Web of Science ®Google Scholar
• van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19(8):810–2. doi:10.1038/s41563-020-0746-0.
   PubMed Web of Science ®Google Scholar
• Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L, Ho DD. Antibody response to Omicron BA.4–BA.5 bivalent booster. N Engl J Med. 2023;388(6):567–9. doi:10.1056/NEJMc2213907.
   PubMed Web of Science ®Google Scholar
• Collier ARY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, Gallup L, Rowe M, Schonberg E, Thai S, et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N Engl J Med. 2023;388(6):565–7. doi:10.1056/NEJMc2213948.
   PubMed Web of Science ®Google Scholar
• Wheatley AK, Fox A, Tan H-X, Juno JA, Davenport MP, Subbarao K, Kent SJ. Immune imprinting and SARS-CoV-2 vaccine design. Trends Immunol. 2021;42(11):956–9. doi:10.1016/j.it.2021.09.001.
   PubMed Web of Science ®Google Scholar
• Guo L, Wang G, Wang Y, Zhang Q, Ren L, Gu X, Huang T, Zhong J, Wang Y, Wang X, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe. 2022;3(5):e348–e56. doi:10.1016/S2666-5247(22)00036-2.
   PubMedGoogle Scholar
• Vardhana S, Baldo L, Morice WG, Wherry EJ. Understanding T cell responses to COVID-19 is essential for informing public health strategies. Sci Immunol. 2022;7(71):eabo1303. doi:10.1126/sciimmunol.abo1303.
   PubMed Web of Science ®Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–501.e15. doi:10.1016/j.cell.2020.05.015.
   PubMed Web of Science ®Google Scholar
• Tarke A, Sidney J, Kidd CK, Dan JM, Ramirez SI, Yu ED, Mateus J, da Silva Antunes R, Moore E, Rubiro P, et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med. 2021;2(2):100204. doi:10.1016/j.xcrm.2021.100204.
   PubMedGoogle Scholar
• Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, Bloom NI, Goodwin B, Phillips E, Mallal S, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022;185(5):847–59 e11. doi:10.1016/j.cell.2022.01.015.
   PubMed Web of Science ®Google Scholar
• Routhu NK, Stampfer SD, Lai L, Akhtar A, Tong X, Yuan D, Chicz TM, McNamara RP, Jakkala K, Davis-Gardner ME, et al. Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates. Sci Immunol. 2023;8:eadg7015. doi:10.1126/sciimmunol.adg7015.
   PubMed Web of Science ®Google Scholar
• Asplund Hogelin K, Ruffin N, Pin E, Månberg A, Hober S, Gafvelin G, Grönlund H, Nilsson P, Khademi M, Olsson T, et al. Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis. iScience. 2021;24(9):103078. doi:10.1016/j.isci.2021.103078.
   PubMed Web of Science ®Google Scholar
• Hermens JM, Kesmir C. Role of T cells in severe COVID-19 disease, protection, and long term immunity. Immunogenetics. 2023;75(3):295–307. doi:10.1007/s00251-023-01294-9.
   PubMed Web of Science ®Google Scholar
• Dowell AC, Ireland G, Zuo J, Moss P, Ladhani S. Association of spike-specific T cells with relative protection from subsequent SARS-CoV-2 Omicron infection in young children. JAMA Pediatr. 2023;177(1):96–7. doi:10.1001/jamapediatrics.2022.3868.
   PubMed Web of Science ®Google Scholar
• Scurr MJ, Lippiatt G, Capitani L, Bentley K, Lauder SN, Smart K, Somerville MS, Rees T, Stanton RJ, Gallimore A, et al. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nat Commun. 2022;13(1):5422. doi:10.1038/s41467-022-32985-8.
   PubMed Web of Science ®Google Scholar
• Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin J-B, Olsson A, Llewellyn-Lacey S, Kamal H, Bogdanovic G, Muschiol S, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158–68.e14. doi:10.1016/j.cell.2020.08.017.
   PubMed Web of Science ®Google Scholar
• Koutsakos M, Reynaldi A, Lee WS, Nguyen J, Amarasena T, Taiaroa G, Kinsella P, Liew KC, Tran T, Kent HE, et al. SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses. Immunity. 2023;56(4):879–92.e4. doi:10.1016/j.immuni.2023.02.017.
   PubMed Web of Science ®Google Scholar
• McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, Liu J, Peter L, Atyeo C, Zhu A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–4. doi:10.1038/s41586-020-03041-6.
   PubMed Web of Science ®Google Scholar
• Kingstad-Bakke B, Lee W, Chandrasekar SS, Gasper DJ, Salas-Quinchucua C, Cleven T, Sullivan JA, Talaat A, Osorio JE, Suresh M, et al. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc Natl Acad Sci USA. 2022;119(20):e2118312119. doi:10.1073/pnas.2118312119.
   PubMed Web of Science ®Google Scholar
• Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, et al. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27(7):1280–9. doi:10.1038/s41591-021-01386-7.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Barouch DH. T cell immunity to COVID-19 vaccines. Sci. 2022;377(6608):821–2. doi:10.1126/science.add2897.
   PubMed Web of Science ®Google Scholar
• Schultheis K, Schaefer H, Yung BS, Oh J, Muthumani K, Humeau L, Broderick KE, Smith TRF. Characterization of guinea pig T cell responses elicited after EP-assisted delivery of DNA vaccines to the skin. Vaccine. 2017;35(1):61–70. doi:10.1016/j.vaccine.2016.11.052.
   PubMed Web of Science ®Google Scholar
• Yung BS, Pugh H, Generotti AA, Phanhthilath N, Schultheis K, Muthumani K, Broderick KE, Smith TRF. Novel IFN-γ ELISpot reveals robust T cell responses elicited after influenza nucleoprotein DNA vaccination in New Zealand White rabbits. Vaccine. 2019;37(7):903–9. doi:10.1016/j.vaccine.2019.01.006.
   PubMed Web of Science ®Google Scholar
• Gao F, Mallajosyula V, Arunachalam PS, van der Ploeg K, Manohar M, Röltgen K, Yang F, Wirz O, Hoh R, Haraguchi E, et al. Spheromers reveal robust T cell responses to the pfizer/BioNTech vaccine and attenuated peripheral CD8+ T cell responses post SARS-CoV-2 infection. Immunity. 2023;56(4):864–78 e4. doi:10.1016/j.immuni.2023.03.005.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215(6):1571–88. doi:10.1084/jem.20171450.
   PubMed Web of Science ®Google Scholar
• Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi:10.1016/j.eclinm.2021.101019.
   PubMedGoogle Scholar
• Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, McCorkell L, Nadkarni GN, Parthasarathy S, Singh U, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934–46. doi:10.1001/jama.2023.8823.
   PubMed Web of Science ®Google Scholar